John Schieffelin
Overview
Explore the profile of John Schieffelin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
306
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bakamutumaho B, Juma J, Clancey E, Nyakarahuka L, Situma S, Odinoh R, et al.
medRxiv
. 2025 Jan;
PMID: 39867400
Introduction: Recent Rift Valley fever (RVF) epidemiology in eastern Africa region is characterized by widening geographic range and increasing frequency of small disease clusters. Here we conducted studies in southwestern...
2.
Drogy M, Glezer C, Engel E, Bond N, Pickett K, Shaffer J, et al.
Am J Trop Med Hyg
. 2024 Dec;
112(3):663-673.
PMID: 39689367
The viral hemorrhagic fevers Lassa fever (LF) and Ebola virus disease (EVD) have been documented to cause long-term health problems in survivors. Limited studies have noted the presence of adverse...
3.
Tong S, Scott J, Eyoh E, Werthmann D, Stone A, Murrell A, et al.
J Allergy Clin Immunol Glob
. 2024 Apr;
3(2):100236.
PMID: 38590754
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes a spectrum of clinical outcomes that may be complicated by severe asthma. Antiviral immunity is often compromised in patients with...
4.
Berry A, Tjaden A, Renteria J, Friedman-Klabanoff D, Hinkelman A, Gibbs M, et al.
Vaccine X
. 2023 Aug;
15:100371.
PMID: 37649617
Introduction: High levels of immunity to SARS-CoV-2 in the community correlate with protection from COVID-19 illness. Measuring COVID-19 antibody seroprevalence and persistence may elucidate the level and length of protection...
5.
DeWitt M, Tjaden A, Herrington D, Schieffelin J, Gibbs M, Weintraub W, et al.
Emerg Infect Dis
. 2022 Dec;
29(1):207-211.
PMID: 36573634
In North Carolina, USA, the SARS-CoV-2 Omicron variant was associated with changing symptomology in daily surveys, including increasing rates of self-reported cough and sore throat and decreased rates of loss...
6.
Uschner D, Bott M, Lagarde W, Keating J, Tapp H, Berry A, et al.
Vaccines (Basel)
. 2022 Nov;
10(11).
PMID: 36423018
We characterize the overall incidence and risk factors for breakthrough infection among fully vaccinated participants in the North Carolina COVID-19 Community Research Partnership cohort. Among 15,808 eligible participants, 638 reported...
7.
Wohl D, Fischer W, Mei W, Zou F, Tozay S, Reeves E, et al.
Clin Infect Dis
. 2022 Sep;
76(3):e835-e840.
PMID: 36065768
Background: Lingering symptoms have been reported by survivors of Ebola virus disease (EVD). There are few data describing the persistence and severity of these symptoms over time. Methods: Symptoms of...
8.
Figueiredo J, Hirsch F, Kushi L, Nembhard W, Crawford J, Mantis N, et al.
Open Forum Infect Dis
. 2022 Jun;
9(6):ofac171.
PMID: 35765315
Background: Global efforts are needed to elucidate the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the underlying cause of coronavirus disease 2019 (COVID-19), including seroprevalence, risk factors, and...
9.
Shantha J, Crozier I, Kraft C, Grant D, Goba A, Hayek B, et al.
PLoS One
. 2021 Jul;
16(7):e0252905.
PMID: 34242218
Background: Following the West African Ebola virus disease (EVD) outbreak of 2013-2016 and more recent EVD outbreaks in the Democratic Republic of Congo, thousands of EVD survivors are at-risk for...
10.
Akpogheneta O, Dicks S, Grant D, Kanneh Z, Jusu B, Edem-Hotah J, et al.
PLoS Negl Trop Dis
. 2021 Mar;
15(3):e0009255.
PMID: 33788861
Background: Despite identification 50 years ago, the true burden of Lassa Fever (LF) across Africa remains undefined for reasons including research focus on hospitalised patients, lack of validated field-feasible tools...